feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Millions Could Benefit From New Long-Acting BP Injection

Millions Could Benefit From New Long-Acting BP Injection

30 Jan

•

Summary

  • A new medication, zilebesiran, is delivered via injection every six months.
  • The drug targets and blocks the production of a specific protein in the liver.
  • This treatment showed potential to help millions manage hard-to-treat high blood pressure.
Millions Could Benefit From New Long-Acting BP Injection

Researchers have found that a new medication, zilebesiran, administered via injection every six months, may offer a significant breakthrough for individuals with hard-to-treat high blood pressure. The KARDIA-2 trial involved 663 participants who received the zilebesiran injection alongside their current hypertension treatments, which had not been fully effective.

Zilebesiran functions by inhibiting the liver's production of angiotensinogen, a protein that causes blood vessels to constrict. By blocking this protein, the medication allows blood vessels to relax, thereby lowering blood pressure. This long-acting treatment offers an alternative to daily medications and could greatly improve hypertension management for many.

Further studies, including KARDIA-3, are planned to assess zilebesiran's effects on individuals with existing cardiovascular disease or those at risk. A large global outcomes study is also slated to investigate its impact on stroke, heart disease, and cardiovascular event risks, with the potential to help millions of patients better manage their condition.

trending

Cognizant profit rises 18.7%

trending

HAL shares tumble after AMCA

trending

Trent share price cautious outlook

trending

JSW Cement Q3 profit rises

trending

Suzlon Energy Q3 results up

trending

BSNL executive trainee recruitment 2026

trending

Qualcomm stock falls on shortages

trending

CTET admit card releasing soon

trending

realme P4 Power 5G launched

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new medication for high blood pressure is called zilebesiran.
The zilebesiran injection is designed to be administered every six months.
Zilebesiran works by stopping the production of angiotensinogen in the liver, which helps blood vessels relax and lowers blood pressure.

Read more news on

Healthside-arrow

You may also like

Novo Nordisk Launches Oral Ozempic in Q2

12 hours ago • 4 reads

article image

First Renal Denervation in India for Uncontrolled BP

29 Jan • 25 reads

article image

Amanita Muscaria: Deadly Fad Masquerading as Health Aid

27 Jan • 26 reads

article image

Gout Drug Fights Heart Attack Risk

26 Jan • 31 reads

article image

Slow Heartbeat? Uncover Bradycardia's Silent Threat

22 Jan • 71 reads

article image